The clinical implication of changing unbound quinidine levels

Area of Science:

• Pharmacology
• Clinical Chemistry
• Cardiology

Background:

• Unbound drug concentrations are crucial for understanding pharmacodynamics and pharmacokinetics.
• Quinidine's clinical application may be influenced by unbound levels.
• Heparin and acute myocardial infarction (AMI) can affect drug binding and elimination.

Purpose of the Study:

• To investigate the pharmacodynamic and pharmacokinetic effects of unbound quinidine levels.
• To assess the impact of heparin administration on unbound quinidine and cardiac electrophysiology.
• To examine changes in quinidine pharmacokinetics during acute myocardial infarction.

Main Methods:

• Electrophysiologic testing in patients receiving quinidine before and after heparin administration.
• Measurement of unbound quinidine concentration, free fatty acids, and right ventricular effective refractory period.
• Pharmacokinetic analysis of quinidine in patients during acute myocardial infarction.

Main Results:

• Heparin significantly increased unbound quinidine concentration and right ventricular effective refractory period, but not total quinidine levels.
• Control patients showed no electrophysiologic changes after heparin.
• During AMI, the unbound quinidine fraction decreased, and half-life reduced, correlating with albumin levels and improved clinical status.

Conclusions:

• Heparin administration enhances unbound quinidine activity within the vascular compartment.
• Changes in quinidine pharmacokinetics during AMI are complex, influenced by clinical status and clearance.
• Interpreting unbound drug concentrations requires consideration of the full clinical context.